Cycloheximide

Catalog No.S7418 Batch:S741801

Technical Data

Formula	C₁₅H₂₃NO₄
Molecular Weight	281.35	CAS No.	66-81-9
Solubility (25°C)*	In vitro	DMSO	56 mg/mL (199.04 mM)
		Ethanol	56 mg/mL (199.04 mM)
		Water	15 mg/mL (53.31 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Cycloheximide, an antifungal antibiotic, is an eukaryote protein synthesis inhibitor with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively. Cycloheximide suppresses ferroptosis and inhibits autophagy.Solutions are unstable and should be fresh-prepared.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
In vitro	Cyclohexamide, a protein synthesis inhibitor, reduces GSIV-induced host cell death by attenuating phosphatidylserine exposure and loss of ΔΨm from apoptosis/necrosis.^[1]
In vivo	Cycloheximide, a protein synthesis inhibitors, acts on memory by altering modulators of memory formation as a secondary consequence of the inhibition of protein synthesis.^[2]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines grouper fin cell line (GF-1) Concentrations 0.33 µg/ml Incubation Time 0-5 days Method Monolayers of GF-1 cells (4.0 mL, 10⁵ cells/mL) on 60-mm Petri dishes are cultivated for at least 20 h, rinsed twice with phosphate buffered saline (PBS), treated with the protein synthesis inhibitor cycloheximide (CHX, 0.33 µg/mL) and ANT inhibitor BKA (20 µM) for 0 5 days, then infected with GSIV K1 strain (multiplicity of infection [m.o.i. ] = 5) for 0 5 days post-infection (dpi). At the end of the incubation period, each sample is removed from the medium and washed with PBS. Cells are then incubated for 10-15 min with 100 µL staining solution.
Animal Study:^{^[2]}	Animal Models Male ICR mice Dosages 30mg/kg, 60mg/kg,120 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
grouper fin cell line (GF-1)
Concentrations
0.33 µg/ml
Incubation Time
0-5 days
Method
Monolayers of GF-1 cells (4.0 mL, 10⁵ cells/mL) on 60-mm Petri dishes are cultivated for at least 20 h, rinsed twice with phosphate buffered saline (PBS), treated with the protein synthesis inhibitor cycloheximide (CHX, 0.33 µg/mL) and ANT inhibitor BKA (20 µM) for 0 5 days, then infected with GSIV K1 strain (multiplicity of infection [m.o.i. ] = 5) for 0 5 days post-infection (dpi). At the end of the incubation period, each sample is removed from the medium and washed with PBS. Cells are then incubated for 10-15 min with 100 µL staining solution.

Animal Study:^{^[2]}

Animal Models
Male ICR mice
Dosages
30mg/kg, 60mg/kg,120 mg/kg
Administration
i.p.

References

[4] Santos DA, et al. Nucleic Acids Res. 2019;47(10):4974-4985.

+ Expand

Selleck's Cycloheximide has been cited by 357 publications

Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer [ Signal Transduct Target Ther, 2024, 9(1):65]	PubMed: 38461173
ESRP1-mediated biogenesis of circPTPN12 inhibits hepatocellular carcinoma progression by PDLIM2/ NF-κB pathway [ Mol Cancer, 2024, 23(1):143]	PubMed: 38992675
Oncogenic fatty acid oxidation senses circadian disruption in sleep-deficiency-enhanced tumorigenesis [ Cell Metab, 2024, 36(7):1598-1618.e11]	PubMed: 38772364
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation [ J Hematol Oncol, 2024, 17(1):77]	PubMed: 39218923
METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma [ J Hematol Oncol, 2024, 17(1):78]	PubMed: 39218945
Engineered a dual-targeting HA-TPP/A nanoparticle for combination therapy against KRAS-TP53 co-mutation in gastrointestinal cancers [ Bioact Mater, 2024, 32:277-291]	PubMed: 37876556
Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors [ Nat Commun, 2024, 15(1):5209]	PubMed: 38890388
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer [ Nat Commun, 2024, 15(1):3445]	PubMed: 38658533
EFHD2 suppresses intestinal inflammation by blocking intestinal epithelial cell TNFR1 internalization and cell death [ Nat Commun, 2024, 15(1):1282]	PubMed: 38346956
Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation [ Cancer Commun (Lond), 2024, 10.1002/cac2.12595]	PubMed: 39030964

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.